Factors To Influence Acquisition Of Herpes

The HSV is highly contagious. Although there are eight different strains, HSV-1 and HSV-2 are responsible for the majority of herpes infections. The cure for herpes symptoms is dependent on which strain of the virus is contracted. The seroprevalence of HSV-2 increases from about 10% at 15-29 years of age to 35% by the age of 60.
When the populations are analyzed according to race, the seroprevalence among African Americans is three- to fourfold higher than among Caucasians. Factors found to influence acquisition of HSV-2 include gender, race, marital status, and place of residence. The highest prevalence of antibodies to HSV-2 in the United States is among female prostitutes and male homosexuals.
The number of sexual partners correlates directly with acquisition of HSV-2. For heterosexual women living with one partner, the probability of acquisition of HSV-2 is less than 10%. The probability increases to 40%, 62%, and over 80% as the number of lifetime sexual partners increases to 2-10, 11-50, or over 50, respectively.
For heterosexual men, similar data are zero probability for one lifetime sexual partner, and 20%, 35%, and 70% for each of the subsequent three risk groups. In contrast, for homosexual men, seroprevalence increases from over 60% to 90% for those with 11-50 partners and over 50 partners. Thus, multiple sexual partners, irrespective of sexual preference, correlates directly with acquisition of HSV-2 infection.
Women have higher rates of infection than men: the estimated risk of a susceptible female contracting HSV from infected males is 80% following a single contact. Among college students, the rate of acquisition is about 2%, compared with an annual rate of 4% for homosexual men. The incidence of HSV-2 infection during pregnancy is about 2.5% per gestation.
Transmission of HSV-2 infection between monogamous sexual partners with discordant infection statuses is 10%-15% yearly. It is important to note that because HSV-2 infection is an ulcerative disease, it is associated with acquisition of HIV, as indicated by increased relative risks of 1.5-2.0.
HSV-2, like HSV-1 infection of the mouth, can be excreted asymptomatically at the time of primary, initial, or recurrent infection. The frequency of clinical recurrences varies somewhat between males and females, with calculations of 2.7 and 1.9 recurrences per 100 days, respectively.
Overall, several studies have implied that the frequency of clinical recurrences is as high as 60%. Among women evaluated prospectively after the first episode of genital herpes, asymptomatic shedding is detected in about 12%, 18%, and 23% of women with primary HSV-1, primary HSV-2, and nonprimary HSV-2 infection, respectively.
For women with established genital HSV-2 infection, asymptomatic shedding is detected on 1%-5% of days when cultures are performed. When PCR is used to evaluate serial genital swabs from women with genital infection, a significant increase in the frequency of HSV DNA shedding is observed, suggesting chronic infection rather than intermittent infection.
Genital HSV infection in pregnant women must be considered separately from that in nonpregnant populations because of the risk to the fetus or newborn. Transmission of infection to the fetus is related to shedding of virus at the time of delivery. The prevalence of excretion at delivery varies from about 0.5% to 1.0% for all women, irrespective of history.
Resistance to all major herpes treatments, such as acyclovir, vidarabine and foscarnet, has been increasingly observed, especially amongst those immuno-compromised. Furthermore, DNA polymerase mutants induced by prolonged or repeated therapy with vidarabine or foscarnet are often resistant to combination therapy with existing compounds for a potentially stronger genital herpes treatment.
These observations underscore the critical importance of our unique treatment for herpes. They are new, highly effective alternative antiviral agents for herpes simplex treatment. The antiviral activity of the OutbreakBalm-Rx brand of herpes treatments is well-documented, and principally due to its direct virucidal effects.
No viral epidemic has ever been stopped by drugs. Synthetic viricides are difficult to manufacture, and none of them appear to be totally effective to date. Most have moderate to severe side effects, while others are carelessly prescribed without accurate long-term safety data available. In contrast, the antiviral properties of medicinal plant extracts particularly for herpes treatment have received considerable attention.
The main pharmacological effects of our anti-herpes treatments are their immunostimulative and antiviral functions. They are devoid of toxicity and negative side effects when used per instructions. To learn more, please go to http://www.forcesofnatureusa.com.